Lifeward to Acquire Powered Upper Body Exoskeleton with AI Capabilities Designed to Restore Function to Stroke Survivors

Core Insights - Lifeward Ltd. has entered into a definitive agreement to acquire technology assets from Skelable Ltd. for a total consideration of $480,000 in Lifeward equity, aimed at enhancing its position as a diversified biomedical innovation company [1] - The acquisition will expand Lifeward's portfolio beyond lower-limb solutions to include a whole-body neuro-rehabilitation portfolio, specifically targeting upper-limb impairments following stroke [1][2] - The integration of Skelable's engineering team, with over 60 years of combined experience, will ensure a disciplined transfer of technology and intellectual property into Lifeward's development framework [1] Technology and Product Development - The acquired technology will enable the commercialization of a powered upper-extremity orthotic system designed to assist individuals with weakened or paralyzed arms and hands, primarily post-stroke [2] - Lifeward expects the new upper body exoskeleton to be ready for commercial launch within approximately 18 to 24 months, following further development and regulatory approvals [3] - The device aims to support therapeutic goals such as muscle re-education and improved range of motion, enhancing patients' ability to perform daily activities [2] Market Opportunity - The acquisition represents a strategic expansion into a significant market opportunity for upper-limb neuro-rehabilitation, addressing a substantial and underserved market with approximately 245,000 newly diagnosed stroke survivors in the U.S. each year experiencing functional impairments [4][8] - Of the over 7 million stroke survivors in the U.S., around two-thirds remain disabled, representing an estimated 4.6 million individuals who could benefit from upper-limb neuro-rehabilitation technologies [4] Commercial Synergies - Lifeward anticipates compelling commercial synergies between the acquired upper-body exoskeleton and its lead product, ReWalk, including overlap in prescriber groups and rehabilitation settings [5][6] - The company expects these synergies to support efficient commercialization and strengthen long-term negotiating leverage with payers [6] Reimbursement and Regulatory Framework - Lifeward believes the upper-limb orthotic program is well positioned within existing U.S. reimbursement frameworks for advanced assistive and neuro-rehabilitation technologies [7] - The company plans to leverage established CMS pathways applicable to upper-extremity powered orthoses and robotic assistive devices [7] Expansion into Adjacent Markets - Beyond stroke rehabilitation, the acquisition positions Lifeward to expand into adjacent neurological and neuromuscular conditions, including spinal cord injury, traumatic brain injury, and multiple sclerosis, each representing meaningful unmet clinical needs [8]